Medici Bjarke R, Nygaard Birte, la Cour Jeppe L, Krakauer Martin, Brønden Andreas, Sonne Mette P, Holst Jens J, Rehfeld Jens F, Vilsbøll Tina, Faber Jens, Knop Filip K
Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Endocr Connect. 2023 Sep 19;12(10). doi: 10.1530/EC-23-0314. Print 2023 Oct 1.
In individuals with hypothyroidism and overweight, levothyroxine substitution therapy is often expected to cause weight loss due to its effect on resting energy expenditure. However, despite levothyroxine-induced enhancement of resting energy expenditure, fat mass loss is rarely seen after levothyroxine substitution therapy. The mechanism behind this conundrum is unknown.
The aim of the study was to assess the effect of levothyroxine therapy on hunger sensations and ad libitum food intake in individuals with hypothyroidism.
Prospective cohort study of 18 newly diagnosed hypothyroid women (thyroid-stimulating hormone (TSH) >10 mU/L). Participants were investigated at diagnosis, after normalization of TSH (<4.0 mU/L), and after 6 months of successful treatment. Eighteen age and body mass index-matched healthy controls were also included.
Hypothyroid individuals were treated with levothyroxine according to European Thyroid Association guidelines.
Changes in hunger sensation were assessed using visual analog scales (cm) before and during a standardized mixed meal test, and food intake was measured during a subsequent ad libitum meal (g).
After 6 months of levothyroxine therapy, mean resting energy expenditure was increased by 144 kcal/day (10%) (P < 0.001). Weight loss was comprised of 0.8 kg fat-free mass while fat mass remained unchanged. Fasting hunger sensation increased from a mean of 4.5 (s.d. 2.2) cm to 5.5 (s.d. 2.2) cm (P = 0.047). The numerical increase in ad libitum meal intake did not reach statistical significance.
Our data suggest that levothyroxine-induced hunger may be a culprit in the lack of fat mass loss from levothyroxine therapy.
在甲状腺功能减退且超重的个体中,由于左甲状腺素替代疗法对静息能量消耗的影响,人们通常期望它能导致体重减轻。然而,尽管左甲状腺素可提高静息能量消耗,但在左甲状腺素替代治疗后很少能看到脂肪量减少。这一难题背后的机制尚不清楚。
本研究的目的是评估左甲状腺素治疗对甲状腺功能减退个体饥饿感和随意进食量的影响。
对18名新诊断的甲状腺功能减退女性(促甲状腺激素(TSH)>10 mU/L)进行前瞻性队列研究。在诊断时、TSH正常化后(<4.0 mU/L)以及成功治疗6个月后对参与者进行调查。还纳入了18名年龄和体重指数匹配的健康对照者。
甲状腺功能减退个体根据欧洲甲状腺协会指南接受左甲状腺素治疗。
在标准化混合餐试验前和试验期间,使用视觉模拟量表(厘米)评估饥饿感的变化,并在随后的随意进餐期间测量食物摄入量(克)。
左甲状腺素治疗6个月后,平均静息能量消耗增加了144千卡/天(10%)(P<0.001)。体重减轻包括0.8千克去脂体重,而脂肪量保持不变。空腹饥饿感从平均4.5(标准差2.2)厘米增加到5.5(标准差2.2)厘米(P = 0.047)。随意进餐摄入量的数值增加未达到统计学意义。
我们的数据表明,左甲状腺素引起的饥饿可能是左甲状腺素治疗后脂肪量未减少的原因。